Blood Pressure Disorders Drug -Global Market Status and Trend Report 2013-2023

Table of Contents

Chapter 1 Overview of Blood Pressure Disorders Drug

• 1.1 Definition of Blood Pressure Disorders Drug in This Report
• 1.2 Commercial Types of Blood Pressure Disorders Drug
  • 1.2.1 Diuretics
  • 1.2.2 Angiotensin Converting Enzyme (ACE) Inhibitors
  • 1.2.3 Angiotensin Receptor Blockers (ARBs)
  • 1.2.4 Others
• 1.3 Downstream Application of Blood Pressure Disorders Drug
  • 1.3.1 Hypertension
  • 1.3.2 Hypotension
  • 1.3.3 Pulmonary Hypertension
• 1.4 Development History of Blood Pressure Disorders Drug
• 1.5 Market Status and Trend of Blood Pressure Disorders Drug 2013-2023
  • 1.5.1 Global Blood Pressure Disorders Drug Market Status and Trend 2013-2023
  • 1.5.2 Regional Blood Pressure Disorders Drug Market Status and Trend 2013-2023

Chapter 2 Global Market Status and Forecast by Regions

• 2.1 Market Development of Blood Pressure Disorders Drug 2013-2017
• 2.2 Production Market of Blood Pressure Disorders Drug by Regions
  • 2.2.1 Production Volume of Blood Pressure Disorders Drug by Regions
  • 2.2.2 Production Value of Blood Pressure Disorders Drug by Regions
• 2.3 Demand Market of Blood Pressure Disorders Drug by Regions
• 2.4 Production and Demand Status of Blood Pressure Disorders Drug by Regions
  • 2.4.1 Production and Demand Status of Blood Pressure Disorders Drug by Regions 2013-2017
  • 2.4.2 Import and Export Status of Blood Pressure Disorders Drug by Regions 2013-2017

Chapter 3 Global Market Status and Forecast by Types

• 3.1 Production Volume of Blood Pressure Disorders Drug by Types
• 3.2 Production Value of Blood Pressure Disorders Drug by Types
• 3.3 Market Forecast of Blood Pressure Disorders Drug by Types

Chapter 4 Global Market Status and Forecast by Downstream Industry

• 4.1 Demand Volume of Blood Pressure Disorders Drug by Downstream Industry
• 4.2 Market Forecast of Blood Pressure Disorders Drug by Downstream Industry

Chapter 5 Market Driving Factor Analysis of Blood Pressure Disorders Drug

• 5.1 Global Economy Situation and Trend Overview
• 5.2 Blood Pressure Disorders Drug Downstream Industry Situation and Trend Overview

Chapter 6 Blood Pressure Disorders Drug Market Competition Status by Major Manufacturers

• 6.1 Production Volume of Blood Pressure Disorders Drug by Major Manufacturers
• 6.2 Production Value of Blood Pressure Disorders Drug by Major Manufacturers
• 6.3 Basic Information of Blood Pressure Disorders Drug by Major Manufacturers
  • 6.3.1 Headquarters Location and Established Time of Blood Pressure Disorders Drug Major Manufacturer
  • 6.3.2 Employees and Revenue Level of Blood Pressure Disorders Drug Major Manufacturer
• 6.4 Market Competition News and Trend
  • 6.4.1 Merger, Consolidation or Acquisition News
  • 6.4.2 Investment or Disinvestment News
  • 6.4.3 New Product Development and Launch

Chapter 7 Blood Pressure Disorders Drug Major Manufacturers Introduction and Market Data

• 7.1 A1M Pharma AB
  • 7.1.1 Company profile
  • 7.1.2 Representative Blood Pressure Disorders Drug Product
  • 7.1.3 Blood Pressure Disorders Drug Sales, Revenue, Price and Gross Margin of A1M Pharma AB
• 7.2 Acceleron Pharma Inc
  • 7.2.1 Company profile
  • 7.2.2 Representative Blood Pressure Disorders Drug Product
  • 7.2.3 Blood Pressure Disorders Drug Sales, Revenue, Price and Gross Margin of Acceleron Pharma Inc
• 7.3 Ache Laboratorios Farmaceuticos SA
  • 7.3.1 Company profile
  • 7.3.2 Representative Blood Pressure Disorders Drug Product
  • 7.3.3 Blood Pressure Disorders Drug Sales, Revenue, Price and Gross Margin of Ache Laboratorios Farmaceuticos SA
• 7.4 Actelion Pharmaceuticals Ltd
  • 7.4.1 Company profile
  • 7.4.2 Representative Blood Pressure Disorders Drug Product
  • 7.4.3 Blood Pressure Disorders Drug Sales, Revenue, Price and Gross Margin of Actelion Pharmaceuticals Ltd
• 7.5 Aerogen Ltd
  • 7.5.1 Company profile
  • 7.5.2 Representative Blood Pressure Disorders Drug Product
  • 7.5.3 Blood Pressure Disorders Drug Sales, Revenue, Price and Gross Margin of Aerogen Ltd
• 7.6 Anavex Life Sciences Corp
  • 7.6.1 Company profile
  • 7.6.2 Representative Blood Pressure Disorders Drug Product
  • 7.6.3 Blood Pressure Disorders Drug Sales, Revenue, Price and Gross Margin of Anavex Life Sciences Corp
• 7.7 AnGes Inc
  • 7.7.1 Company profile
  • 7.7.2 Representative Blood Pressure Disorders Drug Product
  • 7.7.3 Blood Pressure Disorders Drug Sales, Revenue, Price and Gross Margin of AnGes Inc
• 7.8 Arena Pharmaceuticals Inc
  • 7.8.1 Company profile
  • 7.8.2 Representative Blood Pressure Disorders Drug Product
  • 7.8.3 Blood Pressure Disorders Drug Sales, Revenue, Price and Gross Margin of Arena Pharmaceuticals Inc
• 7.9 Ascendia Pharmaceuticals LLC
  • 7.9.1 Company profile
  • 7.9.2 Representative Blood Pressure Disorders Drug Product
  • 7.9.3 Blood Pressure Disorders Drug Sales, Revenue, Price and Gross Margin of Ascendia Pharmaceuticals LLC
• 7.10 Ascendis Pharma A/S
  • 7.10.1 Company profile
  • 7.10.2 Representative Blood Pressure Disorders Drug Product
  • 7.10.3 Blood Pressure Disorders Drug Sales, Revenue, Price and Gross Margin of Ascendis Pharma A/S
• 7.11 AVEO Pharmaceuticals Inc
  • 7.11.1 Company profile
  • 7.11.2 Representative Blood Pressure Disorders Drug Product
  • 7.11.3 Blood Pressure Disorders Drug Sales, Revenue, Price and Gross Margin of AVEO Pharmaceuticals Inc
• 7.12 Bayer AG
  • 7.12.1 Company profile
  • 7.12.2 Representative Blood Pressure Disorders Drug Product
  • 7.12.3 Blood Pressure Disorders Drug Sales, Revenue, Price and Gross Margin of Bayer AG
• 7.13 Bial - Portela & Ca SA
  • 7.13.1 Company profile
  • 7.13.2 Representative Blood Pressure Disorders Drug Product
  • 7.13.3 Blood Pressure Disorders Drug Sales, Revenue, Price and Gross Margin of Bial - Portela & Ca SA
• 7.14 Bioblue Technologies Inc
  • 7.14.1 Company profile
  • 7.14.2 Representative Blood Pressure Disorders Drug Product
  • 7.14.3 Blood Pressure Disorders Drug Sales, Revenue, Price and Gross Margin of Bioblue Technologies Inc
• 7.15 Biogen Inc
  • 7.15.1 Company profile
  • 7.15.2 Representative Blood Pressure Disorders Drug Product
  • 7.15.3 Blood Pressure Disorders Drug Sales, Revenue, Price and Gross Margin of Biogen Inc
• 7.16 Biolab Farmaceutica Ltda
• 7.17 BioRestorative Therapies Inc
• 7.18 Boryung Pharmaceutical Co Ltd
• 7.19 Bristol-Myers Squibb Co
• 7.20 Camurus AB
• 7.21 Capricor Therapeutics Inc
• 7.22 Celsion Corp
• 7.23 Celtaxsys Inc
• 7.24 Chiesi Farmaceutici SpA
• 7.25 Chong Kun Dang Pharmaceutical Corp
• 7.26 Chugai Pharmaceutical Co Ltd
• 7.27 CJ HealthCare Corp
• 7.28 Complexa Inc
• 7.29 Corion Biotech Srl

Chapter 8 Upstream and Downstream Market Analysis of Blood Pressure Disorders Drug

• 8.1 Industry Chain of Blood Pressure Disorders Drug
• 8.2 Upstream Market and Representative Companies Analysis
• 8.3 Downstream Market and Representative Companies Analysis

Chapter 9 Cost and Gross Margin Analysis of Blood Pressure Disorders Drug

• 9.1 Cost Structure Analysis of Blood Pressure Disorders Drug
• 9.2 Raw Materials Cost Analysis of Blood Pressure Disorders Drug
• 9.3 Labor Cost Analysis of Blood Pressure Disorders Drug
• 9.4 Manufacturing Expenses Analysis of Blood Pressure Disorders Drug

Chapter 10 Marketing Status Analysis of Blood Pressure Disorders Drug

• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
  • 10.1.3 Marketing Channel Development Trend
• 10.2 Market Positioning
  • 10.2.1 Pricing Strategy
  • 10.2.2 Brand Strategy
  • 10.2.3 Target Client
• 10.3 Distributors/Traders List

Chapter 11 Report Conclusion

Chapter 12 Research Methodology and Reference

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources